(EMR) Emerson Electric - Ratings and Ratios
Valves, Sensors, Automation, Tools, Software
Dividends
| Dividend Yield | 1.56% |
| Yield on Cost 5y | 3.00% |
| Yield CAGR 5y | 1.19% |
| Payout Consistency | 98.2% |
| Payout Ratio | 35.6% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 25.9% |
| Value at Risk 5%th | 37.8% |
| Relative Tail Risk | -11.22% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.15 |
| Alpha | -13.33 |
| CAGR/Max DD | 0.52 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.516 |
| Beta | 1.233 |
| Beta Downside | 1.353 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.62% |
| Mean DD | 7.88% |
| Median DD | 7.55% |
Description: EMR Emerson Electric December 02, 2025
Emerson Electric Co. (NYSE: EMR) is a diversified technology and software firm that serves process, industrial, and consumer markets worldwide through six operating segments: Final Control, Measurement & Analytical, Discrete Automation, Safety & Productivity, Control Systems & Software, and Test & Measurement. The Final Control segment supplies a broad portfolio of valves, actuators and regulators for process and hybrid industries; Measurement & Analytical offers intelligent instrumentation (e.g., pressure, temperature, flow, corrosion) under the Flexim, Micro Motion and Rosemount brands; Discrete Automation provides solenoid and pneumatic valves, motion solutions, and automation software for discrete manufacturing; Safety & Productivity delivers professional tools for infrastructure and home use; Control Systems & Software integrates plant-wide control platforms such as DeltaV and Ovation; and Test & Measurement sells automated test systems that connect to software for data capture.
Key recent metrics (FY 2024) show total revenue of roughly **$20.5 billion**, a **13 % operating margin**, and free cash flow of about **$2.2 billion**, reflecting steady demand from oil-&-gas, chemicals, and the growing industrial automation market. The company’s exposure to capital-intensive sectors makes it sensitive to global energy spending cycles, while its software-driven automation offerings benefit from the broader **Industry 4.0** trend, which analysts estimate will drive a **~5 % CAGR** in industrial control spending through 2028.
Macro-level drivers include the resurgence of upstream oil and gas projects (especially in North America and the Middle East), tightening environmental regulations that spur demand for emissions-monitoring instrumentation, and a persistent shortage of skilled labor that accelerates adoption of Emerson’s digital automation and remote-monitoring solutions. These factors together underpin a relatively resilient earnings outlook despite cyclical pressures in the process-industry segment.
For a deeper quantitative view, the ValueRay platform provides a granular breakdown of EMR’s valuation multiples and scenario analysis to help you assess the trade-off between growth prospects and valuation risk.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (2.29b TTM) > 0 and > 6% of Revenue (6% = 1.08b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -0.23pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -6.74% (prev 25.44%; Δ -32.18pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 3.10b > Net Income 2.29b (YES >=105%, WARN >=100%) |
| Net Debt (12.21b) to EBITDA (4.95b) ratio: 2.47 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (565.5m) change vs 12m ago -1.55% (target <= -2.0% for YES) |
| Gross Margin 52.84% (prev 50.79%; Δ 2.04pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 41.79% (prev 39.53%; Δ 2.26pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.15 (EBITDA TTM 4.95b / Interest Expense TTM 356.0m) >= 6 (WARN >= 3) |
Altman Z'' 5.42
| (A) -0.03 = (Total Current Assets 8.58b - Total Current Liabilities 9.80b) / Total Assets 41.96b |
| (B) 0.97 = Retained Earnings (Balance) 40.60b / Total Assets 41.96b |
| warn (B) unusual magnitude: 0.97 — check mapping/units |
| (C) 0.08 = EBIT TTM 3.26b / Avg Total Assets 43.10b |
| (D) 1.86 = Book Value of Equity 40.26b / Total Liabilities 21.67b |
| Total Rating: 5.42 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 65.43
| 1. Piotroski 7.0pt |
| 2. FCF Yield 3.16% |
| 3. FCF Margin 14.80% |
| 4. Debt/Equity 0.68 |
| 5. Debt/Ebitda 2.47 |
| 6. ROIC - WACC (= -0.89)% |
| 7. RoE 11.48% |
| 8. Rev. Trend 68.29% |
| 9. EPS Trend 35.94% |
What is the price of EMR shares?
Over the past week, the price has changed by +2.44%, over one month by -0.37%, over three months by +3.11% and over the past year by +3.45%.
Is EMR a buy, sell or hold?
- Strong Buy: 19
- Buy: 3
- Hold: 6
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the EMR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 150.5 | 10.2% |
| Analysts Target Price | 150.5 | 10.2% |
| ValueRay Target Price | 152.5 | 11.6% |
EMR Fundamental Data Overview November 25, 2025
P/E Trailing = 31.8164
P/E Forward = 19.8413
P/S = 4.0055
P/B = 3.5516
P/EG = 1.3672
Beta = 1.25
Revenue TTM = 18.02b USD
EBIT TTM = 3.26b USD
EBITDA TTM = 4.95b USD
Long Term Debt = 8.32b USD (from longTermDebt, last quarter)
Short Term Debt = 4.93b USD (from shortTermDebt, last quarter)
Debt = 13.76b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.21b USD (from netDebt column, last quarter)
Enterprise Value = 84.38b USD (72.16b + Debt 13.76b - CCE 1.54b)
Interest Coverage Ratio = 9.15 (Ebit TTM 3.26b / Interest Expense TTM 356.0m)
FCF Yield = 3.16% (FCF TTM 2.67b / Enterprise Value 84.38b)
FCF Margin = 14.80% (FCF TTM 2.67b / Revenue TTM 18.02b)
Net Margin = 12.73% (Net Income TTM 2.29b / Revenue TTM 18.02b)
Gross Margin = 52.84% ((Revenue TTM 18.02b - Cost of Revenue TTM 8.50b) / Revenue TTM)
Gross Margin QoQ = 51.91% (prev 52.56%)
Tobins Q-Ratio = 2.01 (Enterprise Value 84.38b / Total Assets 41.96b)
Interest Expense / Debt = 0.67% (Interest Expense 92.0m / Debt 13.76b)
Taxrate = 20.10% (160.0m / 796.0m)
NOPAT = 2.60b (EBIT 3.26b * (1 - 20.10%))
Current Ratio = 0.88 (Total Current Assets 8.58b / Total Current Liabilities 9.80b)
Debt / Equity = 0.68 (Debt 13.76b / totalStockholderEquity, last quarter 20.28b)
Debt / EBITDA = 2.47 (Net Debt 12.21b / EBITDA 4.95b)
Debt / FCF = 4.58 (Net Debt 12.21b / FCF TTM 2.67b)
Total Stockholder Equity = 19.97b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.46% (Net Income 2.29b / Total Assets 41.96b)
RoE = 11.48% (Net Income TTM 2.29b / Total Stockholder Equity 19.97b)
RoCE = 11.52% (EBIT 3.26b / Capital Employed (Equity 19.97b + L.T.Debt 8.32b))
RoIC = 8.07% (NOPAT 2.60b / Invested Capital 32.27b)
WACC = 8.95% (E(72.16b)/V(85.92b) * Re(10.56%) + D(13.76b)/V(85.92b) * Rd(0.67%) * (1-Tc(0.20)))
Discount Rate = 10.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.68%
[DCF Debug] Terminal Value 67.81% ; FCFE base≈2.77b ; Y1≈2.52b ; Y5≈2.22b
Fair Price DCF = 48.07 (DCF Value 27.01b / Shares Outstanding 561.8m; 5y FCF grow -11.07% → 3.0% )
EPS Correlation: 35.94 | EPS CAGR: 12.26% | SUE: 0.0 | # QB: 0
Revenue Correlation: 68.29 | Revenue CAGR: 12.17% | SUE: -0.47 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.55 | Chg30d=-0.062 | Revisions Net=-10 | Analysts=19
EPS current Year (2026-09-30): EPS=6.47 | Chg30d=-0.071 | Revisions Net=-13 | Growth EPS=+7.8% | Growth Revenue=+5.2%
EPS next Year (2027-09-30): EPS=7.09 | Chg30d=-0.028 | Revisions Net=-9 | Growth EPS=+9.6% | Growth Revenue=+5.1%
Additional Sources for EMR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle